Piramal Healthcare acquires German blood plasma product
Mumbai, Jul 2 (UNI) Leading Indian pharmaceutical and healthcare company, Piramal Healthcare Limited today announced acquisition of polygeline-based blood plasma products from Germany-based PlasmaSelect AG.
The Company said in a release here that it had arrived at a definite agreement with the German company for polygeline-based blood plasma products marketed under the brand name ''Haemaccel'' in over 38 countries. In addition, PlasmaSelect also marketed the product under the brand name ''Emagel'' in Italy and ''Solucel'' in Venezuela.
This acquisition was intended to bring global leadership to Piramal Healthcare's polygeline-based blood plasma expansion products. Piramal Healthcare currently markets the products under the brand name ''Haemaccel'' in India and under the brand name ''Haemageline'' in 17 other countries.
Blood plasma expansion products are life-saving infusion pharmaceuticals that help maintain blood plasma volume until blood transfusion can be administered to the patient, in the event of blood loss. These products also serve a range of other critical care needs in hospitals and critical care facilities.
The total yearly revenues of Haemaccel and associated brands of Piramal Healthcare and PlasmaSelect together are Euro 9.1 million, at current exchange rates.
Piramal Healthcare would pay cash consideration of Euro 7.7 million for the transaction. The transaction included the brand rights, contracts, registrations, dossiers and know-how relating to Haemaccel and associated brands. It excluded the manufacturing facility of PlasmaSelect at Marburg, Germany. Piramal Healthcare is setting-up a new EDQM and UKMHRA-compliant Haemaccel manufacturing facility at Baddi, India with an initial rated capacity of 4.2 million units. This capacity would be able to service the expanded Haemaccel sales. PlasmaSelect would continue to manufacture Haemaccel as per Piramal Healthcare's requirements to facilitate orderly migration of manufacturing to the new facility at Baddi, India.
Commenting
on
the
acquisition,
Ajay
Piramal,
Chairman
of
Piramal
Group
said
''Over
the
years,
we
have
recognised
the
compelling
potential
of
the
Global
Critical
Care
business.
We
aspire
to
become
a
leading
global
player
in
this
business
with
our
worldwide
distribution
network
and
state-of-the-art
manufacturing
facilities
in
India.
This
acquisition
is
a
stepping
stone
in
that
direction
and
a
reflection
of
our
commitment
to
knowledge
and
innovation,
dynamic
action
and
care
that
empowers
-
consistent
with
our
Group's
values.''
UNI
VK
SSS
SKB1637